Form 4: OptiNose Director Heyman Reports Stock Option Cancellation Following Merger with Paratek Pharmaceuticals

Director Tomas J. Heyman reports cancellation of stock options in OptiNose, Inc. following the merger with Paratek Pharmaceuticals, where each share was converted into cash and contingent value rights.

Summary

• Tomas J. Heyman, a director of OptiNose, Inc., filed a Form 4 detailing changes in beneficial ownership following the merger with Paratek Pharmaceuticals, Inc.
• The merger, effective May 21, 2025, resulted in OptiNose becoming a wholly-owned subsidiary of Paratek.
• Each outstanding share of OptiNose common stock was converted into the right to receive $9.00 in cash and one contingent value right (CVR).
• The CVR represents the right to receive up to $5.00 in cash upon achievement of specified milestones.
• Outstanding stock options were converted into the right to receive cash equal to the excess of $9.00 over the exercise price, if any.
• Stock options with an exercise price greater than $14.00 were cancelled for no consideration.
• Stock options with an exercise price between $9.00 and $14.00 were cancelled and converted into the right to receive one CVR, reduced by the amount the exercise price exceeded $9.00.
• Heyman's stock options with exercise prices of $15.60, $17.70, $29.25, $53.10 and $60.75 were cancelled.

Sentiment

Score: 5

Explanation: The document primarily describes the mechanics of the merger and the impact on stock options. The cancellation of some options is a negative for those holders, but the overall sentiment is neutral as it reflects the completion of a previously announced transaction.

Negatives

• Tomas J. Heyman's stock options in OptiNose with exercise prices exceeding $14.00 were cancelled without any compensation.

Risks

• The value of the CVRs is contingent upon the achievement of specified milestones, which may not be met, resulting in no additional payment to former shareholders and option holders.

Future Outlook

The value of the CVRs depends on the achievement of specific milestones as outlined in the CVR Agreement.

Industry Context

This merger reflects a trend of consolidation in the pharmaceutical industry, where companies seek to expand their product portfolios and pipelines through acquisitions.

Comparison to Industry Standards

• Mergers in the pharmaceutical industry often involve complex valuation structures, including contingent value rights (CVRs) that tie future payments to the achievement of specific milestones, similar to the OptiNose-Paratek deal.
• Comparable companies that have used CVRs in mergers include Sanofi's acquisition of Genzyme and Bristol-Myers Squibb's acquisition of Celgene.
• The success of these deals often hinges on the achievement of the milestones outlined in the CVR agreements, which can be subject to regulatory and market risks.

Stakeholder Impact

• Shareholders received $9.00 in cash and a CVR for each share.
• Option holders with exercise prices above $14.00 received no consideration.
• Option holders with exercise prices between $9.00 and $14.00 received a reduced CVR.

Key Dates

Keywords

Merger, OptiNose, Paratek Pharmaceuticals, Stock Options, Contingent Value Right, CVR, Form 4, Beneficial Ownership, Heyman, Director